{
    "status": "ok",
    "totalResults": 3,
    "articles": [
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.",
            "description": "(marketscreener.com) \nRenovoRx, Inc. , a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company\u2019s Scientific Advisory Board . Dr. Ducreux is the Head of\u2026",
            "url": "https://www.marketscreener.com/quote/stock/RENOVORX-INC-125706124/news/RenovoRx-Expands-Scientific-Advisory-Board-with-Appointment-of-Michel-Ducreux-M-D-Ph-D-45374047/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-16T13:36:01Z",
            "content": "RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D.,\u2026 [+9632 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "RenovoRx (NASDAQ:RNXT) Issues Earnings Results, Beats Estimates By $0.03 EPS",
            "description": "RenovoRx (NASDAQ:RNXT \u2013 Get Free Report) posted its earnings results on Monday. The company reported ($0.27) EPS for the quarter, beating analysts\u2019 consensus estimates of ($0.30) by $0.03, reports. RenovoRx Trading Down 1.6 % RenovoRx stock opened at $0.74 on\u2026",
            "url": "https://www.etfdailynews.com/2023/11/16/renovorx-nasdaqrnxt-issues-earnings-results-beats-estimates-by-0-03-eps/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/renovorx-inc-logo.png?v=20211203091746&w=240&h=240&zc=2",
            "publishedAt": "2023-11-16T14:02:50Z",
            "content": "RenovoRx (NASDAQ:RNXT \u2013 Get Free Report) posted its earnings results on Monday. The company reported ($0.27) EPS for the quarter, beating analysts\u2019 consensus estimates of ($0.30) by $0.03, reports. \r\u2026 [+2433 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights",
            "description": "(marketscreener.com) \nCollaboration with Imugene further validates TAMPTM and will expand use of RenovoRx\u2019s delivery platform beyond chemotherapy to immunotherapy.\n\n\nThe TAMP therapy platform is in a Phase III clinical trial for the treatment of Pancreatic Ca\u2026",
            "url": "https://www.marketscreener.com/quote/stock/RENOVORX-INC-125706124/news/RenovoRx-Reports-Third-Quarter-2023-Financial-Results-and-Operational-Highlights-45348261/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-14T13:32:01Z",
            "content": "Collaboration with Imugene further validates TAMPTM (Trans-Arterial Micro-Perfusion) and will expand use of RenovoRxs delivery platform beyond chemotherapy to immunotherapy.\r\nThe TAMP therapy platfor\u2026 [+17696 chars]"
        }
    ]
}